Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 8/20 | 0.40 |
| ▸ | METAP1 | P53582 | 8/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | BHMT | Q93088 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25471938 | 0.78 | METAP2 (0.38) | METAP2METAP1SLC7A5BHMTNOS2 | |
| SCHEMBL23085771 | 0.78 | SLC7A5 (0.54) | METAP2METAP1SLC7A5BHMTNOS2 | |
| SCHEMBL2128359 | 0.78 | SLC7A5 (0.54) | METAP2METAP1SLC7A5BHMTNOS2 | |
| SCHEMBL14227027 | 0.78 | GRIK1 (0.33) | SLC7A5NOS2NOS1NOS3SLC1A3 | |
| SCHEMBL23760096 | 0.77 | METAP2 (0.38) | METAP2METAP1SLC7A5BHMT | |
| SCHEMBL17324230 | 0.77 | METAP2 (0.37) | METAP2METAP1SLC7A5BHMTNOS2 | |
| SCHEMBL25084405 | 0.77 | METAP2 (0.38) | METAP2METAP1SLC7A5BHMT | |
| SCHEMBL8837368 | 0.73 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL13895431 | 0.73 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL12214830 | 0.73 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387461-A1 | CANCER VACCINE | VICTORIA LINK LIMITED (NZ) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387461-A1 | CANCER VACCINE | TLR9, TLR1, TLR7 | METAP2 2782/4885METAP1 2302/4885SLC7A5 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.